You are here

canakinumab

Novartis bid to repurpose rare disease drug for cancer falls short in third trial

BioPharma Dive

Mon, 08/15/22 - 10:15 am

clinical trials

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

BioPharma Dive

Mon, 10/25/21 - 11:51 pm

clinical trials

Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial

BioSpace

Tue, 03/9/21 - 09:47 pm

clinical trials

metastatic non-small cell lung cancer

Setback for Novartis drug in advanced lung cancer trial

Biopharma Reporter

Tue, 03/9/21 - 10:40 am

clinical trials

metastatic non-small cell lung cancer

Novartis’s canakinumab cancer test approaches

EP Vantage

Fri, 02/12/21 - 11:06 am

non-small cell lung cancer

Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Pharmaceutical Business Review

Wed, 04/29/20 - 10:21 am

clinical trials

ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%

Fierce Pharma

Tue, 03/13/18 - 11:43 am

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

Endpoints

Mon, 11/13/17 - 08:51 pm

Novartis shares slip after mixed heart drug data

Yahoo/Reuters

Mon, 08/28/17 - 09:33 am

cardiovascular disease

Drugmakers face challenges marketing new heart drugs

Medical Marketing and Media

Sat, 07/22/17 - 10:01 am

Details on surprise Novartis heart drug success due Aug 27

Yahoo/Reuters

Thu, 06/29/17 - 09:45 am